Amongst them, KDM6A is a novel relapse-associated gene in AML.324 The reduction of KDM6A expression may decrease ENT1 level and is associated with a decreased cytarabine sensitivity.325 Besides, KDM6A can upregulate TRKA expression through YY1 independent of its demethylation activity, thereby promoting cell resistance to imatinib (Table 3).326 In addition to leukemia, KDM6A is also a key regulator in osteosarcoma, colorectal cancer, and prostate cancer. This evidence concerns the gene KDM6A and prostate carcinoma.